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Abstract 
Androgen receptor mRNA was translated in vitro, and androgen- and antiandrogen-bound receptor complexes were studied 
using limited proteotytic digestion by trypsin. Partial proteolysis of androgen-Lund receptor proteiu resulted in a 29-kDa 
proteolysis-resisting fragment, whereas antiandrogen binding stabilised a 3%kDa fragment. Both fragments contain the entire 
ligand binding domain, and the 35kDa fragment extended into the hinge region of the receptor. Several antiandrogens show 
agonistic properties for a mutated androgen receptor (LNCaP cell variant); trypsin digestion of antiandrogen-bound mutated 
receptor also resulted in a 29-kDa fragment. Our results point to an important difference between antiandrogens and antagonists 
of other steroid hormone receptors. Antiandrogens result in protection of both the hinge region and C-terminus of the androgen 
receptor against proteolytic attack, whereas other studies showed that ~tiestrogens and antiprogestagens expose the C-terminal 
end of the ligand binding domain of their respective receptors to protease. Differences in conformation of the hinge region 
distinguish androgen-bound from antiandrogen-bound receptor complexes, which represents au important feature of antiandro- 
gen action. 
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1. Introduction 
The study of the mechanism of antiandrogen action 
is of great interest, not only because of the therapeutic 
potential of antiandrogens, but also because these 
compounds are important tools to elucidate the molec- 
ular mechanism of action of androgens. Androgens 
initiate effects in target cells through a ligand-activated 
transcription factor, the androgen receptor (AR). Like 
all members of the steroid hormone receptor family, 
the AR binds to its responsive element after a ligand- 
dependent activation process and interacts with the 
transcription complex to regulate gene transcription 
(Carson-Jurica et al., 1990; Smith and Toft, 1993). 
Antiandrogens compete with androgens for binding 
to the AR, but binding of antagonists does not result in 
full transfo~ation of the receptor to a transc~ption- 
ally active form. Several mechanisms for the resulting 
inhibitory effect have been postulated, and recently a 
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subdivision of antagonists in two distinct classes has 
been made (Reese and Katzenellenbogen, 1991; Klein- 
Hitpass et al., 1991; Gronemeyer et al., 1992). One 
class of antagonists does not, or does so with decreased 
efficiency, promote DNA binding of the receptor, 
whereas the other class of antagonists promotes DNA 
binding but induces an abnormal conformation of the 
ligand-binding domain. The latter class of antagonists 
may give rise to a partial agonistic effect, through a 
transcription activation function in the N-terminal do- 
main of the receptor. 
For the progesterone receptor it was recently shown 
that binding of progestagens and antiprogestagens re- 
sults in different susceptibility of the receptor to prote- 
olytic digestion. Antagonists induced protection of a 
smaher progesterone receptor fragment than did ago- 
nists (Allan et al., 1992a,b), and studies with antibodies 
indicated that a short region at the C-terminal end of 
the progesterone receptor is involved in this difference 
(Allan et al., 1992a; Weigel et al., 19921, 
The presented data concern differences in suscepti- 
bility of androgen- and antiandrogen-fund receptor 
complexes to proteolytic digestion. 
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2. Materials and methods 2.3. In vitro transcription and translation 
2.1. Materials 
RNA transcription kit and pBluescript II KS- were 
obtained from Stratagene (La Jolla, USA). Nuclease- 
treated rabbit reticulocyte lysate was purchased from 
Promega (Madison, USA). Lj3’S]methionine @+.a. > 
1000 mCi/mM) was obtained from Amersham 
(Buckinghamshire, UK). Trypsin (type III), soybean 
trypsin inhibitor (type I-S>, goat-anti-mouse agarose 
and goat-anti-rabbit agarose were obtained from Sigma 
(St. Louis, USA). R1881 (methyltrienolone) was pur- 
chased from NEN (Boston, USA). Cyproterone acetate 
was a gift from Schering AG (Berlin, Germany), hy- 
droxyflutamide from Schering USA (Bloomfield, USA) 
and ICI 176.334 (“Casodex”) from ICI Pharmaceuti- 
cals (Macclesfield, UK). Dihydrotestosterone and 
testosterone were obtained from Steraloids (Wilton, 
USA). 
2.2. Plasmid construction 
The coding sequence for the wild-type human AR 
(ARO) was excised from the expression vector pSVAR0 
(Brinkmann et al., 1989) and subcloned in the Sal1 site 
of pBluescript to obtain pBSAR0. The recombinant 
pBSAR0 615-910 was obtained from pBSAR0 after 
digestion with Sac1 and religation. The recombinants 
were linearized with XhoI for transcription. The cod- 
ing sequence for the mutant LNCaP AR CARL) was 
subcloned between the Sal1 and BamHI sites of 
pBluescript (pBSARL). For linearization, the recombi- 
nant was digested with XbaI. 
A 
Both in vitro transcription and in vitro translation in 
the presence of r_-[3sS]methionine were performed ac- 
cording to manufacturer’s instruction. For in vitro tran- 
scription of pBSAR0 and pBSAR0 615-910, T, RNA 
polymerase was used to produce sense mRNA, whereas 
pBSARL was transcribed with T, RNA polymerase. 
2.4. Limited proteolytic digestion of in vitro-produced 
receptors 
Two ~1 of labeled translation mix was pre-incubated 
for 1 h at room temperature with 3 ~1 of ligand 
solution diluted in water. For limited proteolytic diges- 
tion, 5 11 trypsin (40 pg/ml, dissolved in water) was 
added to the pre-incubation mix, followed by an incu- 
bation for 15 min at room temperature. After incuba- 
tion, 20 ~1 SDS sample buffer was added. Samples 
were boiled for 3 min, and 15 ~1 was loaded onto 0.1% 
(w/v) sodium dodecyl sulfate-12.5% (w/v> polyacryl- 
amide gels. After electrophoresis (Laemmli, 1970), the 
gels were vacuum-dried at 80°C for 45 min and autora- 
diography was performed overnight. 
2.5. Immunoprecipitation 
Labeled translation mix (20 ~1) was hormone-treated 
and digested with trypsin as indicated above. After 
digestion, soybean trypsin inhibitor was supplemented 
to a final concentration of 200 pg/ml. Goat-anti-rabbit 
or goat-anti-mouse agarose (100 ~1, diluted 1:4 in 
phosphate-buffered saline (PBS)) was incubated for 2 h 
at 4°C with 1 ~1 of the indicated polyclonal rabbit or 
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Fig. 1. Limited proteolytic digestion of in vitro-produced AR (A) and AR0 615-910 (B) bound with different androgens and antiandrogens. Lane 
1: no trypsin added. Lane 2: control digestion without steroid (-1. Lanes 3-7: 10 nM R1881, 1 PM cyproterone acetate (CA), 10 PM 
hydroxyfiutamide (OH-F), 10 WM ICI 176.334 (ICI 3341, and 10 nM dihydrotestosterone (DHT), respectively. Molecular mass markers are 
indicated at the right. * indicates a non-specific band. 
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monoclonal mouse antiserum. The polyclonal anti- 
serum SP066 (epitope amino acids 892-910) and mon- 
oclonal antiserum F52 (epitope amino acids 593-612) 
were described previously (Zegers et al., 1991; Veld- 
scholte et al., 1992). Following this incubation, the 
resin was washed three times with 1 ml PBS and added 
to the limited proteolytic digest of the receptor. After 
incubation for 2 h at 4 “C, the resin was washed three 
times with 1 ml PBS, and 25 ~1 of sample buffer was 
added. Electrophoresis was performed as described 
above. 
3. Results and discussion 
Limited proteolytic digestion of [ 35S]methionine la- 
beled, in vitro-produced AR was used to detect confar- 
mational changes upon androgen or antiandrogen 
binding to the receptor. The in vitro-produced AR 
showed steroid binding properties similar to those ob- 
served for AR isolated from mammalian cells (Kuiper 
et al., 1993). After incubation of the AR with androgen 
or antiandrogen, a limited amount of trypsin was added 
and the digestion products were analyzed by denatur- 
ing gel electrophoresis. Either in the absence of ligand 
(Fig. 1A) or in the presence of a steroid with no affinity 
for the AR (dexamethasone; result not shown), the AR 
was completely digested to fragments that were unde- 
tectable with electrophoresis. Proteolytic digestion of 
AR incubated either with the synthetic androgen R1881 
or the natural ligands dihydrotestosterone and testos- 
terone, resulted in a 29-kDa proteolysis-resisting frag- 
ment (Fig. lA, result for testosterone not shown). 
Incubation of AR with the antiandrogens cyproterone 
acetate, hydroxyflutamide, or ICI 176.334 before tryp- 
tic digestion resulted in stabilisation of a 35kDa frag- 
ment (Fig. 1A). The concentrations of the different 
ligands used varied according to their differences in 
relative binding affinities of the ligands for the AR 
(Veldscholte et al., 1992). 
Formation of a 29-kDa fragment was the result of 
binding of an agonist, whereas stabilisation of a 35-kDa 
fragment indicated binding of an antagonist. When 
increasing concentrations of the antiandrogen ICI 
176.334 were added together with a constant level of 
R1881, digestion with trypsin resulted in less an amount 
of the 29-kDa fragment and an increased amount of 
the 35-kDa fragment (Fig. 2). As predicted from the 
relative binding affinities of the ligands, 50% binding 
inhibition of 1 nM R1881 occurred at 1 PM ICI 
176.334. When the concentration of R1881 was in- 
creased, the 29-kDa fragment reappeared (Fig. 2). 
Several in vitro-produced AR fragments, including a 
35-kDa fragment, were already present before the start 
of the proteolytic digestion, probably due to alternative 
translation initiation. Therefore, the effect of trypsin 
R1881 (nM) - - 1 1 1 1 1 - 100 
ICI 334(uM) - - - 0.01 0.1 1 10 10 10 kDa 
Fig. 2. Competition of 1 nM R1881 with increasing levels of ICI 
176.334 (ICI 334). Ligands were bound to the in vitro-produced AR 
before digestion with trypsin. Lane 1: no trypsin added. Lane 2: 
control digestion without steroid. Lanes 3-9: indicated levels of 
R1881 and/or ICI 176.334. Molecular mass markers are indicated at 
the right. * indicates a non-specific band. 
on the 35-kDa fragment was studied in detail in sepa- 
rate experiments. A mutant AR cDNA, deleted of the 
N-terminal and DNA-binding domains (AR0 615-9101, 
was translated in vitro into a predominant 35-kDa 
protein (Fig. 1B). Also for this truncated receptor 
protein, binding of either R1881 or dihydrotestos- 
terone resulted in formation of a 29-kDa fragment 
upon proteolytic digestion, whereas the antiandrogens 
predominantly stabilised the 35-kDa fragment. These 
results show that formation of the 29-kDa fragment is 
not dependent on interaction of the ligand binding 
domain with the N-terminal and DNA-binding do- 
mains. 
From these experiments it can be concluded that 
trypsin treatment of androgen- or antiandrogen-bound 
AR results in different proteolysis-resisting fragments 
which suggest a different structural conformation. 
Comparable, but not similar, observations have been 
made for the progesterone and estrogen receptors 
(Vegeto et al., 1992; Allan et al., 1992a; Beekman et 
al., 1993). In contrast with the results found for the 
AR, antagonist binding to these receptors resulted in 
smaller proteolysis-resisting fragments than obtained 
after agonist binding. 
Immunoprecipitation was performed to determine 
which part of the AR was removed upon conversion of 
the 35-kDa fragment into the 29-kDa fragment. After 
incubation of the full-length AR with ligand, followed 
by limited proteolytic digestion with trypsin, the frag- 
ments resisting proteolysis were immunoprecipitated 
with different antisera (Fig. 3). Neither the 35-kDa 
fragment nor the 29-kDa fragment could be immuno- 
precipitated with the antiserum F52 which recognizes 
an epitope in the DNA-binding domain (Zegers et al., 
1991). Therefore, this epitope appears not to be pre- 
sent in either fragment. The antiserum SP066, raised 
against a peptide at the C-terminus of the AR, recog- 
nizes both fragments, which indicates that the differ- 
ence in size of the 29-kDa and 35-kDa fragments is not 
located at the C-terminus of the AR. 
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These results indicate that, in the AR, a part of the 
hinge region is protected against degradation by trypsin 
in the presence of antiandrogens. This is in contrast 
with the results obtained for the progesterone recep- 
tor, where the C-terminus was only retained during 
proteolytic digestion in the presence of an agonist 
(AIlan et al., 1992a; Weigel et al., 1992). Another study 
(Vegeto et al., 1992) showed that a truncated proges- 
terone receptor, with a C-terminal deletion of 42 amino 
acid residues, could not bind a progestagen but still 
bound the antiprogestagen RU486. In addition, RU486 
was able to act as an agonist in a transcription activa- 
tion assay. 
LNCaP prostate tumor cells contain an AR (ARL) 
with a single amino acid change in the steroid binding 
domain (codon 868; Thr-Ala (Veldscholte et al., 1990)). 
Both cyproterone acetate and hydroxyflutamide act as 
agonists for the ARL but ICI 176.334 still behaves as 
an anti~drogen with the ARL (Velds~holte et al., 
19921. ARL is therefore a useful tool to study the 
mechanism of action of antagonists. The in vitro-pro- 
duced ARL was treated with the same androgens and 
antiandrogens as described above for the wild-type AR 
(Fig. 4). For R1881, dihydrotestosterone and ICI 
176.334, the results for ARL were comparable with 
those obtained with the wild-type AR. However, the 
antiandrogens cyproterone acetate and hydroxyflu- 
tamide, which gave rise to a 35kDa fragment with the 
wild-type AR, both induced formation of a 29-kDa 
fragment with the ARL. As these antiandrogens act as 
agonists for the ARL, it can be assumed that the single 
amino acid change in the ARL made it possible for 
R1881 OH-F 
nnnn 
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Fig. 3. Immunoprecipitation of AR fragments with different antisera. 
After treatment with vehicle (-; lanes 3-41, 100 nM R1881 (lanes 
5-6) or 100 nM hydroxyflutamide (OH-F, lanes 7 and 81, the AR was 
digested with trypsin. Lanes 1 and 2 were controls without trypsin. 
After digestion, immunopre~ipitation was performed with the mono- 
cional antiserum F52 (lanes 1,3,5 and 7) or the polyclonal antiserum 
SP066 (lanes 2, 4, 6 and 8). Molecular mass markers are indicated at 
the right. 
kDa 
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Fig. 4. Limited proteolytic digestion of in vitro-produced mutant 
ARL bound with different androgens and antiandrogens. Lane I: no 
trypsin added. Lane 2: control digestion without steroid (-I. Lanes 
3-7: 10 nM R1881,l &I cyproterone acetate (CA), 10 PM hydroxy- 
flutamide (OH-F), 10 PM ICI 176.334 (ICI 3341, and 10 nM dihy- 
drotestosterone (DHT), respectively. Molecular mass markers are 
indicated at the right. * indicates a non-specific hand. 
both antiandrogens to induce a comparable conforma- 
tion as formed after the interaction of an androgen 
with the wild-type AR. 
In conclusion, androgens and antiandrogens induce 
a different change in the conformation of the AR as 
detected by proteolytic digestion. This appears to in- 
volve the hinge region of the receptor, which is in 
contrast with studies on other steroid receptors. Allan 
et al. (1992a) proposed a general action of steroid 
receptor antagonists in preventing the formation of a 
transcriptionally competent conformation of the C- 
terminal end of the ligand binding domain. Conforma- 
tional changes in the C-terminal end of the AR were 
not detected by trypsin treatment although several 
consensus sites for trypsin digestion are present. The 
results therefore suggest a difference in mechanism of 
antiandrogen action compared to other steroid hor- 
mone receptor antagonists. 
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